Fedenia Advisers
RNAC icon

Fedenia Advisers’s Cartesian Therapeutics RNAC Stock Holding History

Fedenia Advisers’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$206K Hold
28,509
– – 0.05% 121
2026
Q2 		$297K Buy
+28,509
New +$211K 0.07% 104

Other funds holding RNAC

Miller Financial Services
Miller Financial Services Marshall, Michigan $132M AUM 10.64% 1-Year Est. Return
Wedbush Securities
Wedbush Securities Los Angeles, California $3.95B AUM 25.45% 1-Year Est. Return
North Star Investment Management
North Star Investment Management Chicago, Illinois $1.85B AUM 21.53% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return
SJS Investment Consulting
SJS Investment Consulting Sylvania, Ohio $993M AUM 16.29% 1-Year Est. Return

Fedenia Advisers's RNAC Position: Q3 2026 in Review

Fedenia Advisers held its Cartesian Therapeutics (RNAC) position steady in Q3 2026 at 28,509 shares worth $206K. The position accounts for 0.05% of the portfolio, ranked #121.

Fedenia Advisers first reported a position in RNAC in Q2 2026 and has held it in 2 quarters since. The position peaked at $297K in Q2 2026. 17 funds tracked by Wall St. Rank hold RNAC as of Q3 2026.

  • Fedenia Advisers held 28,509 shares of Cartesian Therapeutics worth $206K as of Q3 2026.
  • Fedenia Advisers left its Cartesian Therapeutics share count unchanged in Q3 2026.
  • Cartesian Therapeutics made up 0.05% of Fedenia Advisers's portfolio in Q3 2026, its #121 holding.
  • Fedenia Advisers first reported a position in Cartesian Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Fedenia Advisers's Cartesian Therapeutics position peaked at $297K in Q2 2026.
  • 17 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2026.

Based on Fedenia Advisers's 13F filing for Q3 2026, filed 22 Oct 2026.